Lexington, Mass.
Brammer Bio is developing two gene therapy manufacturing facilities in Massachusetts. The company will build out 35,000 sf in an existing 50,000-sf structure in Lexington to create a cGMP manufacturing and quality control operations center. Additionally, Brammer will renovate 8,000 sf in its 66,000-sf commercial cGMP plant in Cambridge to create new production suites to support manufacturing capacity expansion. DPS Group is providing architectural and engineering services for both projects, which are slated for completion in mid-2019.
Source
